Naegleria Fowleri: The Emerging Threat to the Human Brain

Dipiksha Panchal[1*]; Mahesh Rawal[2]; Prasang chandaliya[3]; Manjit Singh[4]; Harshvardhan Singh Parmar[5]; Kiran Joshi[6]; Gopal Kumawat[7]

Sunrise College of Pharmacy, Udaipur
*Corresponding Author

Received:-10 October 2025/ Revised:- 17 October 2025/ Accepted: 25 October 2025/ Published: 31-10-2025

Abstract— Naegleria fowleri, *the so-called "brain-eating amoeba," is a thermophilic free-living amoeboflagellate protozoan that causes Primary Amoebic Meningoencephalitis (PAM) — one of the deadliest human infectious diseases ever documented, with a case fatality rate exceeding 97%. Despite six decades of scientific investigation since its first characterisation in 1965, PAM remains therapeutically refractory, with fewer than ten globally documented survivors. This comprehensive review synthesises current knowledge across all dimensions of* N. fowleri *biology and clinical science: its taxonomy within the phylum Percolozoa; the morphology and functional roles of its trophozoite, flagellate, and cyst forms; its thermophilic ecology and widening environmental distribution; global and Indian epidemiology, including the unprecedented 2024–2025 Kerala outbreak; the molecular mechanisms of olfactory nerve invasion and central nervous system destruction; an expanded catalogue of virulence factors (naegleriapores, Nfa1, cysteine proteases, matrix metalloproteinases); the host innate and adaptive immune response; clinical staging from prodrome to coma; and diagnostic strategies encompassing cerebrospinal fluid (CSF) microscopy, culture, polymerase chain reaction (PCR), and neuroimaging. Therapeutic coverage includes the pharmacological profiles of amphotericin B and miltefosine, CDC-recommended combination regimens, the fundamental challenge of blood–brain barrier penetration, and an appraisal of emerging drug candidates (auranofin, nitroxoline, berberine, and nanotechnology-based delivery systems). The review also evaluates prevention strategies at individual, institutional, and governmental levels, including guidelines from the CDC, WHO, and ICMR. The article concludes with a critical assessment of future research priorities: point-of-care diagnostics, climate-integrated surveillance, paediatric pharmacokinetics, and vaccine development. Given the organism's escalating global epidemiological footprint against a backdrop of climate-driven freshwater warming, a deepened scientific and public health engagement with* N. fowleri *is both timely and imperative.*

Keywords— Naegleria fowleri, Primary Amoebic Meningoencephalitis (PAM), brain-eating amoeba, miltefosine, amphotericin B, thermophilic protozoa, Kerala outbreak, blood–brain barrier, free-living amoeba.

I. INTRODUCTION

Naegleria fowleri occupies a singular position in the landscape of human infectious disease — an organism that is simultaneously omnipresent in natural environments and almost invariably lethal once human infection is established. Colloquially termed the "brain-eating amoeba," this thermophilic free-living amoeboflagellate protozoan is the causative agent of Primary Amoebic Meningoencephalitis (PAM), a fulminant, rapidly progressive infection of the central nervous system (CNS) that advances from prodromal symptoms to fatal brainstem herniation within five to eighteen days. The case fatality rate has persistently exceeded 97% across more than six decades of modern medicine, placing PAM among the most lethal human infections ever characterised.

Within the genus *Naegleria* — which encompasses over 47 environmentally distributed species — *N. fowleri* stands uniquely and categorically apart as the single species definitively and consistently established as a human neuropathogen. This biological uniqueness is not incidental; it reflects a specific constellation of pathogenic attributes that converge to produce a degree of virulence unmatched among free-living environmental organisms: thermal tolerance precisely calibrated to mammalian core body temperature, a nasal portal of CNS entry that bypasses systemic immune surveillance, pore-forming cytolytic peptides

(naegleriapores) capable of osmotic neuronal destruction, and specialised amoebostome structures enabling the physical extraction of cytoplasm from living neurons through trogocytosis.

The epidemiology of PAM presents a paradox: *N. fowleri* is cosmopolitan in distribution, isolated from warm freshwater environments across all inhabited continents, yet human infection is extraordinarily rare. This paradox reflects the uniquely demanding transmission requirements — forcible nasal entry of water carrying viable trophozoites to the olfactory mucosa — rather than any limitation in the organism's pathogenic potential. Once this threshold is crossed, the outcome is almost invariably catastrophic. The explosive proliferation of trophozoites within the structurally confined subarachnoid space, combined with concurrent enzymatic and mechanical tissue destruction, produces bilateral haemorrhagic necrotising meningoencephalitis at a speed unmatched by any other commonly encountered human infection.

From a pharmaceutical perspective, PAM encapsulates some of the most intellectually demanding challenges in contemporary clinical pharmacology: CNS drug delivery across the blood–brain barrier (BBB), selectivity challenges arising from the shared eukaryotic cellular architecture of pathogen and host, drug repurposing methodologies applied to an ultra-rare disease, and management of paediatric emergencies under extreme time pressure. These challenges, combined with *N. fowleri*'s growing epidemiological footprint driven by climate change and the recent emergence of high-mortality outbreaks across South Asia, make a comprehensive, current academic review both scientifically essential and clinically timely.

II. HISTORY AND DISCOVERY OF *NAEGLERIA FOWLERI*

The scientific recognition of *N. fowleri* as a human neuropathogen emerged from a remarkable convergence of independent clinical observations across multiple continents during the mid-1960s, permanently overturning the then-universal scientific consensus that free-living amoebae were incapable of causing disease in immunocompetent mammalian hosts.

The foundational discovery came in 1965, when Fowler and Carter reported six fatal cases of acute meningoencephalitis in children and young adults from South Australia. Conventional microbiological investigations — bacterial culture, viral serology, and fungal microscopy — uniformly failed to identify a pathogen. Post-mortem neuropathological examination revealed a distinctive and previously undescribed pattern: bilateral haemorrhagic necrosis of the olfactory bulbs and anterior cerebral cortex, with motile amoebic trophozoites identifiable in cerebrospinal fluid (CSF) wet preparations and brain tissue sections. Carter's subsequent experimental studies — reproducing lethal meningoencephalitis in mice through intranasal amoeba inoculation — fulfilled the functional equivalent of Koch's postulates for a eukaryotic pathogen. The organism was formally named *Naegleria fowleri* in 1970 in honour of Dr. Malcolm Fowler, the neuropathologist central to characterising these inaugural cases.

Contemporaneously and independently, Butt (1966) documented the first North American cases in Florida, and Cerva and Novak (1968) reported cases in Czechoslovakia, establishing that PAM was not geographically restricted to Australasia. Culbertson (1971) provided the theoretical framework by demonstrating that multiple free-living amoeba genera were capable of experimental CNS infection, embedding *N. fowleri* within the broader concept of "amphizoic amoebae" — organisms capable of both autonomous environmental existence and opportunistic parasitism.

The 1970s and 1980s were characterised by rapid expansion of the PAM case registry through CDC surveillance and by foundational immunofluorescence-based diagnostics developed by Visvesvara and colleagues. The molecular era began with restriction fragment length polymorphism (RFLP) analysis in the late 1980s and progressed to internal transcribed spacer (ITS)-based ribosomal DNA sequencing, revealing at least eight genetically distinct *N. fowleri* genotypes with non-uniform global distributions. Real-time PCR, introduced in the 2000s, transformed diagnostic turnaround from days to hours. The critical therapeutic inflection point came in 2013, when the first patient treated with miltefosine as part of a combination regimen survived, establishing this oral alkylphosphocholine as the cornerstone of contemporary PAM therapy.

III. TAXONOMY AND CLASSIFICATION

Current taxonomic consensus, informed by molecular phylogenetics of ribosomal DNA and comparative genomics, positions *N. fowleri* within the phylum Percolozoa (synonymous with Heterolobosea in older nomenclature), a deeply divergent clade within the eukaryotic supergroup Excavata. Unlike the true Amoebozoa — which encompasses *Acanthamoeba* and *Balamuthia mandrillaris* — the Percolozoa represents an ancient phylogenetic lineage characterised by hybrid amoeboflagellate biology and mitochondria with flattened, discoid cristae. The genus *Naegleria* encompasses more than 47 described species; only *N. fowleri* is definitively established as a human pathogen.

TABLE 1
ACCEPTED TAXONOMIC CLASSIFICATION OF *NAEGLERIA FOWLERI* BASED ON MOLECULAR PHYLOGENETICS

Taxonomic Rank	Classification
Domain	Eukaryota
Clade	Discoba / Excavata
Phylum	Percolozoa (syn. Heterolobosea)
Class	Eutetramitea
Order	Naegleriida
Family	Naegleriidae
Genus	*Naegleria* Alexeieff, 1912
Species	*N. fowleri* (Carter 1970, emend. John 1982)
Common name	Brain-eating amoeba
Natural habitat	Warm freshwater, moist soil, groundwater

IV. MORPHOLOGY OF TROPHOZOITE, CYST, AND FLAGELLATE

N. fowleri exists in three morphologically, functionally, and ecologically distinct developmental stages. Mastery of these forms is foundational to both clinical diagnosis and environmental surveillance.

4.1 Trophozoite — The Pathogenic Stage

The trophozoite is the sole pathogenic, metabolically active, and replicating form of the organism. Ranging from 10 to 35 micrometres in diameter, trophozoites display the classic limax amoeboid morphology and move through tissue via broad, eruptive pseudopodia termed lobopodia. A single, large nucleus containing a prominently centralised karyosome surrounded by a clear halo and peripheral chromatin rim is the definitive morphological identifier under phase-contrast microscopy — the key landmark for recognition in CSF wet mounts. The trophozoite surface expresses specialised cup-shaped phagocytic structures termed amoebostomes (food cups), which mediate contact-dependent trogocytosis of neuronal material. Trophozoites divide by binary fission with a generation time of 8–10 hours at 37°C and are rapidly inactivated below 10°C or above 47°C.

4.2 Flagellate — The Dispersal Stage

The flagellate form is a transient, non-replicating, non-feeding morphological adaptation induced by hypotonic stress or marked ionic concentration shifts. Transformation from the trophozoite to the pear-shaped biflagellate form occurs within 1–4 hours of triggering and is fully reversible. Twin anterior flagella enable rapid aquatic motility that facilitates environmental dispersal. Flagellate forms are occasionally identified in CSF during active PAM but do not contribute directly to CNS tissue destruction.

4.3 Cyst — The Dormant Survival Stage

The environmentally resistant cyst forms when trophozoites are exposed to cold, desiccation, or nutritional deprivation. Morphologically spherical (7–15 μm), the cyst's double-layered wall contains ostioles that enable excystation when conditions improve. Cysts survive for months at 4°C, resist modest free chlorine concentrations, and can be transported as airborne soil particles. Critically, cysts do not form within human CNS tissue during PAM — disease progression is too rapid — so their absence from histological sections does not exclude *N. fowleri* from the differential diagnosis.

TABLE 2
COMPARATIVE MORPHOLOGICAL AND FUNCTIONAL FEATURES OF THE THREE *N. FOWLERI* DEVELOPMENTAL STAGES

Feature	Trophozoite	Flagellate	Cyst
Size	10–35 μm	10–16 μm	7–15 μm
Shape	Irregular (limax-type)	Pear-shaped (biflagellate)	Spherical
Motility	Directional via lobopodia	Rapid via flagella	Non-motile
Nucleus	Single; large central karyosome	Single; prominent nucleolus	Single; condensed
Pathogenicity	Exclusively pathogenic	Non-pathogenic	Non-pathogenic
Function	Feeding, replication, infection	Environmental dispersal	Dormancy, stress survival
Trigger	Warm, nutrient-rich water	Hypotonic/ionic shift	Cold, starvation, desiccation

V. LIFE CYCLE

The life cycle of *N. fowleri* encompasses continuous cycling among its three developmental forms in response to environmental conditions, with the human CNS representing an inadvertent and terminal ecological dead-end for the organism. Under favourable warm conditions (>25°C), the organism exists predominantly as actively dividing trophozoites in freshwater biofilm matrices where bacterial prey — particularly cyanobacteria during summer bloom events — is abundant. As temperatures fall or nutrients deplete, trophozoites encyst; cysts may then be aerosolised as airborne soil particles and deposited in new aquatic habitats. Flagellate transformation occurs as a transient response to ionic stress, enabling rapid positional redistribution. Human infection is not part of the organism's natural life cycle; it occurs when viable trophozoites are inadvertently introduced into the nasal cavity through forcible water contact, initiating the pathogenic cascade described below.

VI. ENVIRONMENTAL DISTRIBUTION

N. fowleri has been isolated from freshwater environments across all inhabited continents, demonstrating extraordinary ecological adaptability. The organism thrives in warm freshwater lakes, rivers, ponds, geothermal springs, inadequately disinfected swimming pools, water parks, and industrial thermal effluents. It colonises biofilms within building hot water plumbing at temperatures between 25°C and 50°C. Groundwater systems represent a perennial reservoir, with cysts capable of surviving extended periods in cold water and being mobilised upon temperature rise. Environmental ubiquity stands in stark contrast to the rarity of human infection, underscoring the role of specific nasal exposure mechanics — rather than mere proximity to contaminated water — as the decisive infection determinant.

Chlorination effectiveness is critically temperature-dependent. At water temperatures above 30°C — routinely encountered in outdoor pools and domestic plumbing during summer — free chlorine residuals decay substantially faster, reducing disinfection capacity precisely when *N. fowleri* proliferation is maximal. Detection methods for environmental surveillance include real-time qPCR targeting 5.8S rDNA and ITS regions, direct microscopy and culture on non-nutrient agar, and, increasingly, metagenomic water analysis.

VII. THERMOPHILIC NATURE AND CLIMATE CHANGE IMPACT

The thermophilic character of *N. fowleri* is its defining ecological and epidemiological trait. Trophozoites demonstrate optimal growth at 37–42°C — precisely matching mammalian core body temperature — with a growth range extending from a minimum of approximately 25°C to a maximum of 46°C. This thermal preference directly produces strong seasonal clustering of PAM cases in summer months and concentrates risk in warm-climate regions. Cysts, by contrast, exhibit cold-temperature survival for months, enabling long-term environmental persistence across seasons.

Climate change is an increasingly significant ecological driver for *N. fowleri* range expansion. Sustained warming of freshwater surface temperatures across the Northern Hemisphere is extending the annual duration of thermophilic proliferation and expanding the geographic envelope of PAM-conducive habitats. Cases documented in Minnesota (2012) and Indiana (2017) — US states historically considered climatically unsuitable for *N. fowleri* — provide direct epidemiological evidence of northward geographic range expansion. Mathematical modelling projections indicate that continued warming at current rates will substantially increase the proportion of Northern Hemisphere populations exposed to PAM-conducive environmental conditions by mid-century. In South and Southeast Asia, where ambient temperatures are already permissive year-round, climate change compounds an already high-risk environment.

TABLE 3
THERMAL TOLERANCE PARAMETERS OF *N. FOWLERI* TROPHOZOITES AND CYSTS UNDERPINNING PUBLIC HEALTH WATER MANAGEMENT RECOMMENDATIONS

Temperature Parameter	Value / Outcome
Minimum growth temperature	~25°C (growth arrested below this threshold)
Optimal growth temperature	37–42°C (equivalent to mammalian core body temperature)
Maximum tolerable temperature	~46°C (transient viability maintained)
Rapid trophozoite death	Below 10°C or above 47°C for >24 hours
Cyst cold survival	Months at 4°C (metabolically dormant; viable)
Trophozoite thermal inactivation (water)	Above 60°C sustained for several minutes
Cyst chlorine resistance	Resistant to standard pool chlorination (0.5–1 mg/L)
Chlorine to kill trophozoites	~1 mg/L free chlorine within 30 min at 25°C, pH 7

VIII. GLOBAL EPIDEMIOLOGY

PAM is a globally documented but geographically unequally distributed disease. The United States maintains the most comprehensive national surveillance dataset: 154 confirmed cases from 1937 to 2024, with a case fatality rate consistently exceeding 97%. The demographic profile is strikingly consistent — 85% male, 75% under 18 years of age, 90% associated with recreational freshwater swimming or diving, seasonally concentrated between July and September, and geographically clustered in southern states including Texas, Florida, Arizona, and California.

Beyond the United States, confirmed or probable PAM cases have been documented in Australia (19 cases), India (rapidly rising, now estimated at ≥50), Pakistan (17 cases), Mexico, Venezuela, New Zealand, multiple European nations, and isolated reports from Africa and the Middle East. The true global burden substantially exceeds confirmed case numbers due to widespread absence of molecular diagnostic infrastructure in endemic low-resource settings, where PAM is systematically underdiagnosed as bacterial meningitis.

TABLE 4
GLOBAL DISTRIBUTION OF LABORATORY-CONFIRMED PAM CASES (1937–2024). TRUE BURDEN SUBSTANTIALLY EXCEEDS CONFIRMED FIGURES DUE TO UNDERDIAGNOSIS

Country / Region	Confirmed Cases	Case Fatality	Primary Exposure Route
United States	154	>97%	Freshwater swimming/diving (southern states)
India	≥50 (rising rapidly)	75–97%	Freshwater bathing + nasal irrigation
Pakistan	17	>95%	Nasal ablution (wudu) with tap water
Australia	19	>97%	Freshwater swimming/diving
Mexico	9	>97%	Freshwater swimming
New Zealand	9	>97%	Freshwater swimming
Europe (multiple)	~7	>97%	Freshwater / geothermal pools
Other/unclassified	~40	~95–99%	Mixed

IX. INDIA AND KERALA OUTBREAK CASES

India's PAM burden has escalated dramatically in recent years, and the 2024–2025 Kerala cluster constitutes the largest and most systematically documented *N. fowleri* outbreak ever recorded in the country. Kerala's combination of tropical climate, abundant warm freshwater bodies, cultural bathing and ritual cleansing practices, and dense population proximity to water bodies creates a uniquely high-risk epidemiological environment.

The Kerala outbreak was characterised by cases distributed across multiple districts, affecting a wide demographic range from young children to middle-aged adults. The Government of Kerala responded by issuing formal state-level technical guidelines (G.O. Rt. No. 1760/2024) — the first such regulatory response to an *N. fowleri* outbreak in India — establishing clinical diagnostic protocols, emergency drug access pathways, and mandatory reporting frameworks. The Indian Council of Medical Research (ICMR) concurrently updated national guidelines to incorporate *N. fowleri* into routine differential diagnosis of acute meningoencephalitis and initiated central procurement of miltefosine for emergency distribution to designated PAM treatment centres.

TABLE 5
DISTRICT-WISE PAM CASE DISTRIBUTION IN KERALA, INDIA, 2024–2025 OUTBREAK (G.O. RT. NO. 1760/2024)

District	Reported Cases	Confirmed Deaths	Notable Features
Thiruvananthapuram	15	3	Includes 17-yr-old; multiple clusters
Kollam	12	4	48-yr-old woman; 62-yr-old man (Oct. 2025)
Kozhikode	10	3	9-yr-old child (Aug. 2025); 47-yr-old male
Malappuram	8	2	55-yr-old woman on ventilator
Kannur	6	1	3.5-yr-old child in ICU
Other districts	~53	~10	Progressive case ascertainment ongoing
STATE TOTAL	**~104**	**~23**	**Largest confirmed Kerala cluster on record**

X. TRANSMISSION ROUTES

N. fowleri is classified as an amphizoic organism — capable of both independent environmental existence and opportunistic parasitism of mammalian hosts. Unlike most human neurological pathogens, it requires no biological vector, has no vertebrate animal reservoir, and is not transmitted between humans by any known route. Two biologically plausible transmission pathways have been established through epidemiological and experimental evidence.

10.1 Water-Borne Route

The predominant transmission pathway, accounting for approximately 93–95% of cases with an identifiable exposure source, involves nasal contact with contaminated water during activities that generate sufficient nasal water pressure to deliver trophozoites to the olfactory mucosa. Associated activities include head-submersion swimming or diving in warm natural freshwater, use of inadequately chlorinated recreational pools and water parks, and nasal irrigation (neti pots, nasal douching, ritual wudu) using untreated or inadequately treated tap water. Cases attributable to treated municipal water systems have been documented in Louisiana, Texas, and Pakistan — where inadequate chlorine residuals within household plumbing at high ambient temperatures permitted *N. fowleri* proliferation to infective concentrations.

10.2 Dust-Borne Route

Approximately 5–7% of PAM cases occur without identifiable water exposure, supporting an alternative aerosol- or dust-mediated transmission pathway. Desiccated *N. fowleri* cysts embedded within fine soil or clay particles may be inhaled, deposited on the nasal mucosa, and excyst into trophozoites that initiate infection. This route is relatively more prevalent in arid, dusty, high-temperature regions, including parts of the Indian subcontinent; its existence means water safety measures alone are insufficient to prevent all cases.

XI. RISK FACTORS

The principal epidemiologically identified risk factors for PAM include: recreational freshwater swimming, diving, or water sports in warm natural water bodies during summer months; forcible nasal water contact during head-submersion activities; nasal irrigation with untreated or inadequately treated tap water; male sex (reflecting greater participation in high-risk water activities); young age (5–14 years is the modal demographic in US surveillance data); ambient water temperature above 25°C; exposure in poorly maintained or inadequately chlorinated pools; geothermal spring bathing; domestic hot water systems maintained below the 60°C disinfection threshold; and geographic residence in warm-climate regions. Drought conditions that reduce water body volume and raise temperatures further amplify seasonal risk.

An important and unresolved epidemiological paradox is the near-universal environmental exposure to *N. fowleri* in endemic areas coupled with a near-zero infection rate. Individual susceptibility variation based on host genetic factors, innate immune parameters, nasal anatomy, or microbiome composition has not been conclusively demonstrated. The weight of evidence indicates that infection threshold is primarily determined by exposure mechanics — the volume and velocity of water delivered to the olfactory mucosa — rather than by host-specific susceptibility factors.

XII. PATHOGENESIS — NOSE TO BRAIN INVASION

The pathophysiology of PAM can be conceptualised as three sequential and mechanistically distinct phases, each occurring within a clinically compressed timeframe that leaves minimal window for therapeutic intervention.

Phase 1: Nasal Colonisation and Neuroepithelial Penetration

Upon deposition on the nasal mucosa, *N. fowleri* trophozoites adhere to the olfactory neuroepithelium through lectin-mediated, galactose-inhibitable surface interactions. Cathepsin B — a lysosomal cysteine protease expressed at the food cups and leading pseudopodium — degrades the mucosal glycoprotein barrier, while matrix metalloproteinases (MMP-2 and MMP-9) digest type IV collagen in the epithelial basement membrane, enabling trophozoite penetration into the subepithelial olfactory nerve bundles. Simultaneously, secreted cysteine proteases degrade secretory IgA — the predominant mucosal immunoglobulin — disabling first-line humoral immunity before systemic immune activation can be mobilised.

Phase 2: Olfactory Nerve-Mediated CNS Migration

Having breached the olfactory neuroepithelium, trophozoites migrate centripetally along olfactory nerve axons (cranial nerve I) through the foramina of the cribriform plate — a perforated bony partition separating the nasal cavity from the anterior cranial fossa — to reach the olfactory bulbs in the subarachnoid space. Experimental models employing fluorescently labelled trophozoites document histological presence within the olfactory bulbs as early as 24 hours after intranasal instillation.

Emerging molecular evidence identifies a G protein-coupled receptor homologue (NF0059410) expressed by *N. fowleri* that is structurally homologous to the human muscarinic M1 receptor — binding acetylcholine to generate active chemotaxis directed toward olfactory nerve tissue, providing a molecular mechanism for the organism's consistent neurotropism.

Phase 3: CNS Invasion, Exponential Proliferation, and Haemorrhagic Destruction

Upon reaching the subarachnoid space and CSF, trophozoites encounter an optimal growth environment at body temperature. Binary fission with a doubling time of 8–10 hours generates exponential population growth within a structurally enclosed anatomical space. Naegleriapores (pore-forming cytolytic peptides), phospholipases, and neuraminidases simultaneously destroy neural tissue through multiple parallel mechanisms. The macroscopic result is fulminant bilateral haemorrhagic necrotising meningoencephalitis — maximal in the olfactory bulbs and anterior frontal lobes, progressing to the cerebellum, brainstem, and spinal cord in advanced cases. Progressive cerebral oedema, raised intracranial pressure, transtentorial herniation, and brainstem compression culminate in death from respiratory failure and cardiovascular collapse.

XIII. VIRULENCE FACTORS

N. fowleri deploys an expansive, multi-level virulence arsenal that enables tissue invasion, immune evasion, and rapid neuronal destruction. These molecular determinants are described below and summarised in Table 6.

TABLE 6
PRINCIPAL VIRULENCE DETERMINANTS OF *N. FOWLERI* AND THEIR MOLECULAR MECHANISMS OF PATHOGENIC ACTION

Virulence Factor	Molecular Identity	Mechanism of Pathogenic Action
Naegleriapores (A, B, C)	Pore-forming cytolytic peptides	Insert into host membrane bilayers; create non-selective ion channels; osmotic lysis of neurons and glial cells
Nfa1 protein	13.1 kDa amoebostome surface protein	Mediates contact adhesion and trogocytosis; antibody blockade significantly reduces cytotoxicity
Nf23 protein	23 kDa surface-expressed protein	Expressed 40,000-fold higher than in *N. gruberi*; contributes to cytopathic effects; validated vaccine target
Cathepsin B (NfCB)	Lysosomal cysteine protease	Degrades mucins, ECM proteins, IgA; activates NLRP3 inflammasome-driven neuroinflammation
Phospholipases A and C	Secreted hydrolytic enzymes	Hydrolyse host membrane phospholipids; generate cytotoxic lysophospholipids and free fatty acids
MMP-2, MMP-9, MMP-14	Matrix metalloproteinases	Digest basement membrane type IV collagen; enable olfactory neuroepithelial penetration
Neuraminidase	Glycohydrolase	Cleaves sialic acid from host membrane glycoproteins; disrupts receptor signalling
NF0059410 (GPCR)	Muscarinic M1 receptor homologue	Responds to acetylcholine; mediates neurotropic chemotaxis toward olfactory nerve tissue
Cysteine proteases (multiple)	Multiple secreted isoforms	Hydrolyse IgA, IgG, IgM; degrade ECM; comprehensive immune evasion

XIV. HOST IMMUNE RESPONSE

The CNS innate immune response to *N. fowleri* invasion is paradoxically both necessary and destructive. Microglia and astrocytes detect amoebic molecular patterns through Toll-like receptor 4 (TLR4) and mount NF-κB-dependent upregulation of pro-inflammatory cytokines — IL-1β, IL-6, TNF-α, and IL-8 — recruiting peripheral neutrophils and monocytes across the disrupted blood–brain barrier. Reactive oxygen species (ROS) generated by activated immune cells non-selectively damage host neurons, while neutrophil extracellular traps (NETs) contribute both to partial amoebic killing and to extensive bystander tissue injury through myeloperoxidase-generated hypochlorous acid.

N. fowleri has evolved sophisticated counter-measures against this response: overexpression of superoxide dismutase and thioredoxin reductase detoxifies ROS produced by the host, while multiple secreted cysteine proteases degrade IgA, IgG, and IgM at both mucosal surfaces and within the CNS. NLRP3 inflammasome activation by *N. fowleri* cathepsin B amplifies IL-1β production, creating a self-reinforcing inflammatory cascade that destroys host neural tissue while failing to eliminate the amoeba. This immunopathological mechanism — wherein the host's own hyperinflammatory response substantially amplifies

neuronal death beyond that caused by the amoeba's direct cytotoxic activity alone — is a defining feature of PAM pathology and provides a theoretical rationale for adjunctive anti-inflammatory therapy.

XV. CLINICAL MANIFESTATIONS AND SYMPTOMS

PAM is characterised by explosive symptom onset and relentless neurological deterioration, typically completing the full clinical course — from initial symptoms to death — within 5–18 days. The prodromal presentation is clinically indistinguishable from bacterial meningitis, with the critical exception that early anosmia (loss of smell) and ageusia (loss of taste) — reflecting direct olfactory nerve damage at the initial invasion site — can provide a distinguishing diagnostic clue when sought in the context of freshwater nasal exposure.

TABLE 7
CLINICAL STAGING OF PAM WITH CORRESPONDING PATHOLOGICAL CORRELATES

Stage	Timing (post-exposure)	Key Clinical Features	Pathological Basis
Prodromal	Days 1–5	Severe frontal/retro-orbital headache; high fever; nausea; vomiting; anosmia; ageusia	Olfactory epithelial invasion; early meningeal irritation
Acute Meningitis	Days 3–7	Nuchal rigidity; photophobia; phonophobia; positive Kernig's and Brudzinski's signs; behavioural change	Subarachnoid invasion; CSF pleocytosis; early cerebral oedema
Encephalitic	Days 5–10	Disorientation; seizures; olfactory hallucinations; focal deficits; cranial nerve palsies; ataxia	Frontal lobe haemorrhagic necrosis; raised ICP
Terminal	Days 7–18	Deepening coma; fixed dilated pupils; cardiovascular instability; apnoea; death	Transtentorial herniation; brainstem compression; widespread haemorrhagic encephalitis

Post-mortem neuropathological findings are highly characteristic and considered pathognomonic: bilateral haemorrhagic necrosis of the olfactory bulbs, diffuse frontal lobe haemorrhagic necrosis, leptomeningeal haemorrhagic exudate, and widespread cerebral oedema. Histologically, trophozoites are identifiable in perivascular spaces and subarachnoid areas; cyst forms are absent.

XVI. DIAGNOSTIC METHODS (CSF, PCR, IMAGING)

16.1 Clinical Suspicion and Diagnostic Triad

PAM diagnosis is among the most challenging in clinical infectious disease medicine, owing to its clinical mimicry of bacterial meningitis, extreme rarity limiting clinician familiarity, and dependence on specialised laboratory capabilities. The irreplaceable prerequisite is a high index of clinical suspicion. The diagnostic algorithm begins with recognition of the characteristic clinical-epidemiological triad: (1) acute-onset meningoencephalitis with fever, severe headache, and rapidly progressive neurological deterioration; (2) history of nasal exposure to warm freshwater within 1–7 days preceding symptom onset; and (3) failure to identify a bacterial, viral, or fungal pathogen on initial workup. When two or more elements of this triad are present, PAM-specific investigations and empirical antiamoebic treatment must be initiated simultaneously without awaiting laboratory confirmation.

16.2 CSF Analysis and Direct Microscopy

Lumbar puncture with CSF analysis is the cornerstone initial investigation. Characteristic findings include markedly elevated opening pressure, turbid to haemorrhagic appearance, neutrophilic pleocytosis (100–20,000 WBC/μL), significantly elevated protein (100–1,000 mg/dL), markedly reduced glucose (<45 mg/dL), and elevated RBC count — all in the presence of a critically important negative Gram stain. Direct wet mount microscopy of fresh, warm, uncentrifuged CSF at 10× and 40× magnification can identify motile trophozoites (10–35 μm) with active lobopodial movement and a centrally located karyosome; this must be performed immediately before chilling causes loss of motility and morphological rounding that mimics erythrocytes or lymphocytes.

16.3 PCR and Molecular Diagnostics

Real-time quantitative PCR (qPCR) targeting the 5.8S ribosomal DNA and flanking ITS1/ITS2 regions is the diagnostic gold standard, with sensitivity and specificity both exceeding 99%. The US CDC offers 24-hour emergency qPCR with same-day results. Multiplex PCR panels simultaneously testing for *N. fowleri*, *Acanthamoeba* spp., and *Balamuthia mandrillaris* are

commercially available. Next-generation metagenomic CSF sequencing represents an emerging technology capable of pathogen identification without prior targeted probe design, potentially transformative in resource-limited settings.

16.4 Neuroimaging

MRI is preferred over CT for superior soft-tissue resolution. Characteristic findings include T2/FLAIR hyperintensity in the olfactory bulbs (highly specific when present), frontal cortex, basal ganglia, and periaqueductal grey; leptomeningeal gadolinium enhancement; and diffusion-restricted cortical/subcortical areas on DWI. CT demonstrates effacement of basal cisterns, bilateral frontal hypodensity, and sulcal obliteration. Olfactory bulb signal abnormality on MRI in the context of freshwater exposure and acute meningoencephalitis constitutes a radiological red flag requiring immediate treatment initiation regardless of confirmatory test status.

XVII. CURRENT TREATMENT STRATEGIES

No drug holds formal regulatory approval specifically for PAM. All pharmacological management is off-label and empirical, derived from in vitro susceptibility data, animal model results, and retrospective analysis of fewer than ten documented survival cases. The paramount clinical principle is that treatment must begin immediately upon clinical suspicion, without awaiting laboratory confirmation.

TABLE 8
PHARMACOLOGICAL PROFILES OF PRINCIPAL DRUGS USED IN PAM MANAGEMENT (ALL AGENTS OFF-LABEL; NO FDA APPROVAL FOR PAM INDICATION)

Liposomal AmB (L-AmB)	Polyene antifungal	Binds amoebic membrane sterols → osmotic lysis	IV: 3–5 mg/kg/day	Preferred formulation; superior CNS penetration; reduced nephrotoxicity
Conventional AmB	Polyene antifungal	Same as L-AmB; also intrathecal use	IV 1 mg/kg/day; IT 1.5 mg/day	Intrathecal route bypasses BBB directly
Miltefosine	Alkylphosphocholine	Inhibits phosphatidylcholine biosynthesis; disrupts lipid signalling	PO: 50 mg TID (≥45 kg)	Only oral CNS-active amoebicidal agent; available via CDC emergency access
Fluconazole	Triazole antifungal	Inhibits CYP51 ergosterol synthesis	IV/PO: 800–1200 mg/day	Excellent CNS penetration; CYP3A4 interaction with rifampicin
Azithromycin	Macrolide antibiotic	Inhibits 50S ribosomal subunit; >90% in vitro growth inhibition	IV/PO: 500 mg/day	Good CNS distribution; included in all recent survival cases
Rifampicin	Rifamycin	Inhibits DNA-dependent RNA polymerase	PO: 600 mg/day	Potent CYP3A4 inducer; may reduce fluconazole levels
Dexamethasone	Corticosteroid	Anti-inflammatory; reduces cerebral oedema	IV: 0.6 mg/kg/day divided q6h	Used in most survivors; controversial immunosuppressive effect
Mannitol 20%	Osmotic diuretic	Osmotically reduces ICP	IV: 0.5–1 g/kg PRN	Adjunctive ICP management; no direct amoebicidal activity

XVIII. MILTEFOSINE AND COMBINATION THERAPY

Miltefosine (hexadecylphosphocholine) is an oral alkylphosphocholine originally developed as an antineoplastic agent and subsequently repurposed for visceral leishmaniasis (FDA approval 2014). It is now the most pharmacologically promising agent for PAM treatment. Its multifactorial amoebicidal mechanism encompasses inhibition of phosphatidylcholine biosynthesis (disrupting membrane phospholipid homeostasis), disruption of alkyl-lipid metabolism and mitochondrial function, and modulation of intracellular signalling cascades. Critically, miltefosine achieves CSF concentrations exceeding its in vitro minimum amoebicidal concentration — a pharmacokinetic property shared by very few alternative agents. The standard adult oral dose is 50 mg three times daily; paediatric dosing is weight-based. Principal adverse effects include GI intolerance, hepatotoxicity, and teratogenicity (absolutely contraindicated in pregnancy and for 5 months post-treatment).

All documented PAM survivors have received aggressive multi-drug antiamoebic therapy comprising at least three active agents simultaneously, combined with ICU-level neurological monitoring and intracranial pressure management. The 2013

survivor — a 12-year-old girl treated with liposomal amphotericin B, miltefosine, azithromycin, fluconazole, dexamethasone, and therapeutic hypothermia (32–34°C) — established the contemporary template. Subsequent confirmed survivors (2016) have demonstrated that miltefosine-inclusive protocols can achieve survival even without therapeutic hypothermia.

TABLE 9
GLOBALLY DOCUMENTED PAM SURVIVORS AND THERAPEUTIC REGIMENS (1978–2016). THESE FIVE CASES CONSTITUTE THE PRIMARY EVIDENCE BASE FOR CURRENT CDC TREATMENT RECOMMENDATIONS

Case	Year	Patient	Key Agents Used	Outcome
1 — California, USA	1978	9-yr-old female	Conventional AmB (IV+IT) + Miconazole + Rifampicin	Full recovery; first PAM survivor on record
2 — Mexico	2003	Adult male	Conventional AmB + Dexamethasone	Full recovery; AmB alone can occasionally achieve cure
3 — California, USA	2013	12-yr-old female	L-AmB + Miltefosine + Azithromycin + Fluconazole + Dexamethasone + Therapeutic Hypothermia	Full neurological recovery; first miltefosine survivor
4 — New Jersey, USA	2016	8-yr-old male	L-AmB + Miltefosine + Azithromycin + Fluconazole + Rifampicin + Dexamethasone	Full recovery; confirms miltefosine protocol without hypothermia
5 — Arkansas, USA	2016	16-yr-old female	L-AmB + Miltefosine + Fluconazole + Azithromycin + Dexamethasone	Full recovery

XIX. MERGING DRUG THERAPIES

The extreme rarity of PAM and the economic non-viability of de novo drug development have made drug repurposing the dominant strategy in PAM pharmacology. High-throughput screening of FDA-approved compound libraries against *N. fowleri* in vitro has yielded several promising candidates.

TABLE 10
INVESTIGATIONAL AGENTS AND NOVEL DRUG CANDIDATES UNDER PRE-CLINICAL EVALUATION FOR PAM

Agent	Original Class	Stage	Key Pre-clinical Findings
Nitroxoline	Quinoline antibiotic (approved for UTI in Europe)	In vitro + early animal model	Potent amoebicidal activity at clinically achievable concentrations; CNS penetration under evaluation
Auranofin	Gold-based antirheumatic (FDA-approved for RA)	In vitro	Nanomolar inhibition of *N. fowleri* thioredoxin reductase; synergistic with miltefosine in vitro
Berberine	Plant alkaloid	In vitro	Inhibits trophozoite growth; anti-inflammatory properties may reduce immunopathological injury
Chloroquine	Antimalarial (FDA-approved)	In vitro	Disrupts lysosomal pH; amoebicidal at physiologically achievable concentrations; documented CNS penetration
Voriconazole	Triazole antifungal (FDA-approved)	In vitro	Greater intrinsic amoebicidal potency than fluconazole; potential replacement in combination regimens
Anti-Nfa1 mAb	Monoclonal antibody (biological)	In vitro proof-of-concept	Significantly reduces *N. fowleri* cytotoxic activity; first anti-virulence antibody approach
Brain-targeted AmB nanoparticles	Nanomedicine (targeted delivery)	Preclinical animal models	Fourfold higher CNS AmB concentrations vs L-AmB in murine PAM; reduced nephrotoxicity
Atorvastatin	HMG-CoA reductase inhibitor	In vitro	Anti-inflammatory immunomodulatory adjunct; minimal direct amoebicidal activity

Nanotechnology-based delivery systems represent a particularly promising avenue for overcoming the fundamental pharmacological challenge of CNS drug penetration. Lipid nanoparticles surface-conjugated with active brain-targeting ligands (transferrin receptor antibodies, apolipoprotein E peptides, angiopep-2) engage receptor-mediated transcytosis across the BBB, delivering amphotericin B or miltefosine to CNS tissue at concentrations substantially exceeding those achieved with conventional IV formulations. Preclinical data from murine PAM models document fourfold higher CNS amphotericin B

concentrations with brain-targeted nanoparticles compared to L-AmB, representing a potentially transformative pharmacokinetic advance.

XX. BLOOD–BRAIN BARRIER CHALLENGES

The blood–brain barrier (BBB) — comprising cerebral endothelial cells with specialised tight junctions (claudins, occludins, ZO proteins), astrocyte end-feet, and pericytes — constitutes the principal pharmacological obstacle in PAM therapy. The BBB restricts most hydrophilic and large-molecular-weight compounds from achieving therapeutic CNS concentrations, limiting available antiamoebic agents to those with sufficient lipophilicity, molecular weight, and plasma protein binding profiles compatible with significant BBB penetration.

An important but complex dynamic in active PAM is BBB disruption by the inflammatory process itself. *N. fowleri* enzymatic activity and the host hyperinflammatory response mechanically and biochemically degrade the BBB, potentially increasing passive permeability to drugs that would otherwise have minimal CNS penetration. However, this same disruption drives cerebral oedema, haemorrhage, and intracranial hypertension, paradoxically limiting effective drug distribution within oedematous parenchyma. The result is an unpredictable and patient-variable pharmacokinetic environment that makes rational dose optimisation extremely challenging.

Strategies to overcome BBB limitations include: intrathecal and intraventricular administration of conventional amphotericin B, which directly deposits drug into the CSF compartment, bypassing the BBB entirely; liposomal formulations that preferentially distribute to CNS-reticuloendothelial tissue; active receptor-mediated transcytosis using surface-engineered nanoparticles; and chemical modification of candidate molecules to enhance lipophilicity without compromising amoebicidal potency. The BBB challenge also explains why CNS-penetrant agents such as miltefosine and fluconazole have theoretical therapeutic advantages over agents with otherwise superior in vitro potency but poor CNS pharmacokinetics.

XXI. PREVENTION AND PUBLIC HEALTH MEASURES

21.1 Individual Protective Measures

Individual-level risk reduction centres on preventing nasal entry of potentially contaminated water. Key measures include: use of nose clips or maintaining the head above water during swimming, diving, and water sports in warm natural freshwater bodies; avoidance of forcible nose-first water entry; avoidance of disturbing bottom sediments during water activities (where *N. fowleri* concentrations are highest); refraining from freshwater activities when surface water temperatures exceed 25°C in endemic areas; and exclusive use of sterile, distilled, or boiled-and-cooled water for nasal irrigation, neti pots, and ritual nasal ablution.

21.2 Water Safety and Disinfection

TABLE 11
RECOMMENDED WATER DISINFECTION STANDARDS FOR *N. FOWLERI* CONTROL ACROSS DIFFERENT WATER SETTINGS

Water Setting	Recommended Measure	Target Parameter	Efficacy Notes
Public swimming pools	Continuous chlorination + pH control	Free $Cl_2 \geq 1$–3 mg/L; pH 7.2–7.8	Kills trophozoites; limited cyst effect; UV supplementation recommended
Municipal water systems	Residual chlorination throughout distribution	Free $Cl_2 \geq 0.2$–0.5 mg/L at consumer tap	Rapid decay >30°C; booster stations required in hot climates
Domestic hot water	Maintain thermostatic storage temperature	≥60°C throughout system	Kills trophozoites; controls *Legionella* simultaneously
Nasal irrigation water	Use only sterile / distilled / boiled water	Pathogen-free	Boil 1 minute (3 minutes at altitude); 0.2-µm filter acceptable
Natural recreational bodies	Environmental qPCR monitoring + public advisories	*N. fowleri* PCR-negative or risk-stratified	No practical environmental treatment; behavioural modification only
Hydrotherapy/therapeutic pools	Closed-loop filtration + UV + continuous Cl_2	Free $Cl_2 \geq 2$ mg/L; UV 40 mJ/cm²	Highest standards required; vulnerable patient populations

XXII. CDC, WHO, AND ICMR GUIDELINES

22.1 CDC Guidelines

The US Centers for Disease Control and Prevention maintains the most comprehensive PAM clinical guidance globally. CDC recommendations include: emergency 24-hour qPCR testing with same-day results through the Division of Foodborne, Waterborne, and Environmental Diseases; 24-hour access to miltefosine from the Strategic National Stockpile via a dedicated physician hotline; empirical combination therapy initiation without awaiting confirmation in any patient with the diagnostic triad; and a summer freshwater advisory recommending nose clips for head-submersion activities. The CDC also maintains systematic national surveillance, updates geographic risk maps based on confirmed cases, and issues public communications during significant individual cases.

22.2 WHO Guidelines

The World Health Organization's *Guidelines for Safe Recreational Water Environments* (Volume 1) establishes foundational international standards for *N. fowleri* control in freshwater recreational settings. WHO recommends minimum free chlorine residuals of ≥1 mg/L at pool point-of-use, pH maintenance between 7.2 and 7.8 for optimal chlorine efficacy, and risk-stratified public advisory frameworks for natural freshwater bodies based on environmental temperature and surveillance data. WHO Technical Notes on Drinking-Water, Sanitation and Hygiene formally classify *N. fowleri* as a recognised drinking water pathogen requiring consideration in water safety plans.

22.3 ICMR Guidelines

India's Indian Council of Medical Research issued updated national guidelines in 2024 formally incorporating *N. fowleri* into the routine differential diagnosis of acute meningoencephalitis in Indian hospitals — a landmark institutional recognition of PAM as a domestic public health priority. ICMR guidelines establish: protocols for emergency miltefosine access through central procurement mechanisms; standardised CSF collection and wet mount microscopy protocols for hospital laboratories; referral pathways for confirmatory qPCR at ICMR-networked reference centres; and mandatory reporting requirements for suspected and confirmed PAM cases to facilitate national surveillance. State-level responses — exemplified by Kerala's G.O. Rt. No. 1760/2024 — complement national guidelines with region-specific surveillance and clinical management frameworks.

XXIII. FUTURE RESEARCH PERSPECTIVES

Despite meaningful recent scientific advances, fundamental challenges in *N. fowleri* research and PAM management will persist for the foreseeable future, defining a rich and urgent research agenda.

Clinical trial feasibility: PAM's extreme rarity (2–3 confirmed annual cases in the US; ~15–25 globally) makes randomised controlled trial comparison of treatment regimens numerically and ethically infeasible. Knowledge will continue to derive from prospective case series and platform adaptive trial designs. International multi-centre data-sharing platforms — pooling survival case analyses across endemic countries including India, Pakistan, the US, and Australia — represent the most realistic near-term approach to generating comparative effectiveness evidence.

Point-of-care diagnostics: The development of ASSURED-compliant (Affordable, Sensitive, Specific, User-friendly, Rapid, Equipment-free, Delivered) lateral flow antigen detection tests for *N. fowleri* would be transformative for resource-limited endemic settings where molecular laboratory infrastructure is absent and PAM is systematically misdiagnosed as bacterial meningitis.

Genomic and drug target development: Whole-genome comparative analysis of multiple *N. fowleri* strains has identified pathogen-specific genes with no human homologue — the most pharmacologically selective drug target class. The Nfa1 and Nf23 surface proteins, naegleriapores, the GPCR NF0059410 (acetylcholine receptor homologue), and cathepsin B represent validated, structurally characterised targets for both small-molecule drug discovery and monoclonal antibody-based passive immunotherapy.

Climate-integrated surveillance: Longitudinal, geographically diverse environmental monitoring networks documenting freshwater temperature trends alongside concurrent *N. fowleri* population dynamics are essential to quantify real-time responses of PAM risk to climate change and to validate or refute mathematical predictive models. Integration of satellite-based surface water temperature monitoring with environmental qPCR surveillance represents a technically achievable and cost-effective approach to early warning systems for PAM risk escalation.

Paediatric pharmacology: Age-stratified pharmacokinetic studies of miltefosine and other candidate PAM agents in children — the predominant patient demographic — are urgently needed to establish evidence-based paediatric dosing protocols rather than continued reliance on weight-based extrapolation from adult data.

Vaccine development: Although ambitious given disease rarity, the identification of immunogenic, *N. fowleri*-specific surface proteins (Nfa1, Nf23, naegleriapores) with no human homologues provides a rational basis for proof-of-concept vaccine evaluation in murine PAM models. Anti-Nfa1 monoclonal antibodies have already demonstrated proof-of-concept amoebicidal activity in cell culture; passive immunisation strategies warrant systematic in vivo evaluation.

XXIV. CONCLUSION

Naegleria fowleri exemplifies a biological paradox that challenges modern medicine: a microscopically small, environmentally ubiquitous organism capable of defeating the immunological and pharmacological arsenal of the 21st century with near-perfect consistency. Six decades of sustained scientific investigation have illuminated its biology, ecology, pathogenesis, and therapeutic vulnerabilities in remarkable detail, yet the case fatality rate remains obstinately above 97%, and the global case burden is growing rather than declining.

This review has synthesised current knowledge across all dimensions of *N. fowleri* science: its phylogenetically ancient taxonomy within Percolozoa; the morphological elegance of its three developmental forms; the thermophilic ecology that makes rising global temperatures an increasingly powerful epidemiological driver; its expanding geographic distribution documented by cases in previously non-endemic northern US states and by the unprecedented 2024–2025 Kerala outbreak; the molecular choreography of its nasal-to-brain invasion pathway; and its sophisticated virulence arsenal — naegleriapores, Nfa1-mediated trogocytosis, cathepsin B-driven immune evasion, and GPCR-mediated neurotropic chemotaxis.

On the diagnostic and therapeutic fronts, real-time PCR has transformed detection speed and sensitivity, miltefosine has introduced the first genuinely new pharmacological class into PAM management in decades, and combination regimen optimisation has produced a small but statistically significant cohort of survivors. Yet fundamental barriers remain: a diagnostic window compressed to hours by explosive disease progression; BBB pharmacokinetics that prevent reliable CNS drug delivery; an absence of validated treatment response biomarkers; and global inequity in access to miltefosine and molecular diagnostics.

Two overarching messages emerge from this review. First, PAM is a preventable disease — the singular, well-defined transmission route means that informed public behaviour, rigorous water quality management, and accessible safe-water technologies can prevent virtually all cases. The gap between this preventability and the ongoing case toll is a remediable failure of public awareness, clinical education, and institutional infrastructure. Second, *N. fowleri* is an organism whose epidemiological trajectory is unfavourable in a warming world. The investment required to close the diagnostic, therapeutic, and preventive gaps — in research funding, regulatory facilitation, international data sharing, and health system capacity building — is modest relative to the human tragedy of every preventable PAM death. The scientific and public health communities must act with the urgency that a 97% fatality rate demands.

REFERENCES

[1] World Health Organization. (2011). *Naegleria fowleri*. In *WHO technical notes on drinking-water, sanitation and hygiene in emergencies*. WHO.

[2] Yoder, J. S., Straif-Bourgeois, S., Roy, S. L., Moore, T. A., Visvesvara, G. S., Ratard, R. C., & Hill, V. R. (2012). Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. *Clinical Infectious Diseases*, *55*(9), e79–e85. https://doi.org/10.1093/cid/cis626

[3] Visvesvara, G. S., Moura, H., & Schuster, F. L. (2007). Pathogenic and opportunistic free-living amoebae: *Acanthamoeba* spp., *Balamuthia mandrillaris*, *Naegleria fowleri*, and *Sappinia diploidea*. *FEMS Immunology & Medical Microbiology*, *50*(1), 1–26.
https://doi.org/10.1111/j.1574-695X.2007.00232.x

[4] Cope, J. R., & Ali, I. K. (2016). Primary amebic meningoencephalitis: What have we learned in the last 5 years? *Current Infectious Disease Reports*, *18*(10), Article 31. https://doi.org/10.1007/s11908-016-0545-8

[5] Capewell, L. G., Harris, A. M., Yoder, J. S., Cope, J. R., Eddy, B. A., Roy, S. L., Visvesvara, G. S., Fox, L. M., & Beach, M. J. (2015). Diagnosis, clinical course, and treatment of primary amoebic meningoencephalitis in the United States, 1937–2013. *Journal of the Pediatric Infectious Diseases Society*, *4*(4), e68–e75. https://doi.org/10.1093/jpids/piu103

[6] Centers for Disease Control and Prevention. (2024). *Naegleria fowleri — Primary amebic meningoencephalitis (PAM)*. https://www.cdc.gov/parasites/naegleria/

[7] Siddiqui, R., & Khan, N. A. (2014). Primary amoebic meningoencephalitis caused by *Naegleria fowleri*: An old enemy presenting new challenges. *PLOS Neglected Tropical Diseases*, *8*(8), Article e3017. https://doi.org/10.1371/journal.pntd.0003017

[8] Siddiqui, R., Maciver, S. K., & Khan, N. A. (2025). *Naegleria fowleri*: Emerging therapies and translational challenges. *Expert Review of Anti-Infective Therapy*, *23*(9), 753–761. https://doi.org/10.1080/14787210.2025.2498312

[9] Fowler, M., & Carter, R. F. (1965). Acute pyogenic meningitis probably due to *Acanthamoeba* sp.: A preliminary report. *British Medical Journal*, *2*(5464), 740–742. https://doi.org/10.1136/bmj.2.5464.740

[10] Visvesvara, G. S. (1991). Free-living amebae as opportunistic agents of human disease. *Journal of Neuropathology and Experimental Neurology*, *50*(3), 195–211. https://doi.org/10.1097/00005072-199105000-00001

[11] Carter, R. F. (1972). Primary amoebic meningoencephalitis: An appraisal of present knowledge. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, *66*(2), 193–213. https://doi.org/10.1016/0035-9203(72)90143-0

[12] De Jonckheere, J. F. (2011). What do we know by now about the ecology and biology of the pathogenic free-living amoeba *Naegleria fowleri*? *Experimental Parasitology*, *128*(1), 19–22. https://doi.org/10.1016/j.exppara.2011.01.009

[13] Linam, W. M., Ahmed, M., Cope, J. R., Chu, C., Visvesvara, G. S., da Silva, A. J., Qvarnstrom, Y., & Green, J. (2015). Successful treatment of an adolescent with *Naegleria fowleri* primary amebic meningoencephalitis. *Pediatrics*, *135*(3), e744–e748. https://doi.org/10.1542/peds.2014-2292

[14] Cope, J. R., Conrad, D. A., Cohen, N., Cotter, M., da Silva, A., Jackson, J., & Visvesvara, G. S. (2016). Use of the novel therapeutic agent miltefosine for the treatment of primary amebic meningoencephalitis. *Clinical Infectious Diseases*, *62*(6), 774–776. https://doi.org/10.1093/cid/civ1029

[15] Kemble, S. K., Lynfield, R., DeVries, A. S., Drehner, D. M., Pomputius, W. F., Beach, M. J., Visvesvara, G. S., & Smith, K. E. (2012). Fatal *Naegleria fowleri* infection acquired in Minnesota: Possible expanding range of a deadly thermophilic organism. *Clinical Infectious Diseases*, *54*(6), 805–809. https://doi.org/10.1093/cid/cir961

[16] Marciano-Cabral, F., MacLean, R., Mensah, A., & LaPat-Polasky, L. (2003). Identification of *Naegleria fowleri* in recreational waters and sediment of the United States Gulf Coast. *Journal of Eukaryotic Microbiology*, *50*(Suppl.), 715–716. https://doi.org/10.1111/j.1550-7408.2003.tb00671.x

[17] Government of Kerala, Department of Health and Family Welfare. (2024). *Technical guidelines on prevention, diagnosis and management of amoebic meningoencephalitis* (G.O. Rt. No. 1760/2024/H&FWD).

[18] Indian Council of Medical Research. (2024). *ICMR guidelines for diagnosis and management of Naegleria fowleri infections*.

[19] Culbertson, C. G. (1971). The pathogenicity of soil amoebas. *Annual Review of Microbiology*, *25*, 231–254. https://doi.org/10.1146/annurev.mi.25.100171.001311

[20] Schuster, F. L., & Visvesvara, G. S. (2004). Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. *International Journal for Parasitology*, *34*(9), 1001–1027. https://doi.org/10.1016/j.ijpara.2004.06.004

[21] Yoder, J. S., Eddy, B. A., Visvesvara, G. S., Capewell, L., & Beach, M. J. (2010). The epidemiology of primary amoebic meningoencephalitis in the USA, 1962–2008. *Epidemiology and Infection*, *138*(7), 968–975. https://doi.org/10.1017/S0950268809991014

[22] Fritz-Laylin, L. K., Prochnik, S. E., Ginger, M. L., Dacks, J. B., Carpenter, M. L., Field, M. C., Kuo, A., Paredez, A., Chapman, J., Pham, J., Shu, S., Neupane, R., Cipriano, M., Mancuso, J., Tu, H., Salamov, A., Lindquist, E., Shapiro, H., Lucas, S., ... Dawson, S. C. (2010). The genome of *Naegleria gruberi* illuminates early eukaryotic versatility. *Cell*, *140*(5), 631–642. https://doi.org/10.1016/j.cell.2010.01.032

[23] Debnath, A., Tunac, J. B., Silva-Olivares, A., Galindo-Gómez, S., Shibayama, M., & McKerrow, J. H. (2012). *In vitro* efficacy of auranofin alone and in combination against *Naegleria fowleri*. *Antimicrobial Agents and Chemotherapy*, *56*(5), 2861–2863. https://doi.org/10.1128/AAC.06430-11

[24] Bhatt, K., Bhatt, D. K., & Bhatt, U. K. (2021). Emerging drug candidates for primary amoebic meningoencephalitis: A review. *Journal of Parasitology Research*, *2021*, Article 6698752. https://doi.org/10.1155/2021/6698752

[25] Lainhart, W., & Cerva, L. (2013). Identification of environmental *Naegleria fowleri* by real-time PCR in the southeastern United States. *Applied and Environmental Microbiology*, *79*(10), 3350–3354. https://doi.org/10.1128/AEM.00252-13

[26] De Jonckheere, J. F. (2002). A century of research on the amoeboflagellate genus *Naegleria*. *Acta Protozoologica*, *41*, 309–342.

[27] Khan, N. A. (2006). *Naegleria fowleri*: Biology and pathogenesis. *Microbes and Infection*, *8*(1), 167–173. https://doi.org/10.1016/j.micinf.2005.06.024

[28] Siddiqui, R., Saleem, S., & Khan, N. A. (2012). Virulence factors of *Naegleria fowleri* and pathogenesis of PAM. *Expert Review of Anti-Infective Therapy*, *10*(7), 765–769. https://doi.org/10.1586/eri.12.62

[29] John, D. T. (1982). Primary amebic meningoencephalitis and the biology of *Naegleria fowleri*. *Annual Review of Microbiology*, *36*, 101–123. https://doi.org/10.1146/annurev.mi.36.100182.000533

[30] Rohr, U., Weber, S., Michel, R., Selenka, F., & Wilhelm, M. (1998). Comparison of free-living amoebae in hot water systems of hospitals. *Applied and Environmental Microbiology*, *64*(5), 1822–1824. https://doi.org/10.1128/AEM.64.5.1822-1824.1998

[31] De Jonckheere, J. F., Brown, S., Robinson, B. S., & Dobson, P. J. (1988). Identification of *Naegleria* species by restriction endonuclease digestion of whole-cell DNA. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, *82*(2), 224–227. https://doi.org/10.1016/0035-9203(88)90415-2

[32] Marciano-Cabral, F. (2004). The immune response to *Naegleria fowleri* amebae and pathogenesis of infection. *FEMS Immunology & Medical Microbiology*, *40*(1), 25–36. https://doi.org/10.1016/S0928-8244(03)00280-1

[33] Siddiqui, R., Bhatt, K., Ahmed, K., & Khan, N. A. (2016). Olfactory neuroepithelium: The main portal of entry for *Naegleria fowleri*. *Annals of Clinical Microbiology and Antimicrobials*, *15*(1), Article 42. https://doi.org/10.1186/s12941-016-0155-6

[34] Siddiqui, R., Ali, I. K., Cope, J. R., & Khan, N. A. (2016). Biology and pathogenesis of *Naegleria fowleri*. *Acta Tropica*, *164*, 375–394. https://doi.org/10.1016/j.actatropica.2016.09.022

[35] Ahmad, A. F., Cope, J. R., & Ali, I. K. (2015). Recent advances in the pathogenesis of *Naegleria fowleri* and possibilities of new drug targets. *Journal of Eukaryotic Microbiology*, *62*(4), 523–531. https://doi.org/10.1111/jeu.12218

[36] Deetz, T. R., Sawyer, M. H., Billman, G., Schuster, F. L., & Visvesvara, G. S. (2003). Successful treatment of *Naegleria fowleri* meningoencephalitis: Clinical review. *Clinical Infectious Diseases*, *36*(10), 1267–1272. https://doi.org/10.1086/374838

[37] Schuster, F. L., & Visvesvara, G. S. (2004). Opportunistic amoebae: Challenges in prophylaxis and treatment. *Drug Resistance Updates*, *7*(1), 41–51. https://doi.org/10.1016/j.drup.2004.01.002

[38] Siddiqui, R., Bhatt, K., Bhatt, D. K., & Khan, N. A. (2020). Towards identification of potential drug targets in *Naegleria fowleri*. *ACS Infectious Diseases*, *6*(2), 121–132. https://doi.org/10.1021/acsinfecdis.9b00367

[39] Kolar, S. S., Mehta, R. T., Bhatt, D. K., & Bhatt, K. (2021). Nanoparticle-mediated drug delivery strategies for amebic infections. *Expert Opinion on Drug Delivery*, *18*(7), 923–934. https://doi.org/10.1080/17425247.2021.1867103

[40] Borkens, Y. (2024). The pathology of the brain eating amoeba *Naegleria fowleri*. *Indian Journal of Microbiology*, *64*(3), 1384–1394. https://doi.org/10.1007/s12088-024-01264-1

[41] Ali, S., Al-Islam, K. M. N., Murad, M. W., & Tithi, T. (2025). A comprehensive narrative review of *Naegleria fowleri* infections: Emerging epidemiology, molecular pathogenesis and therapeutic advances (2020–2025). *Asian Journal of Research in Medical and Pharmaceutical Sciences*, *14*, 143–163.

[42] Dai, L., Guo, X. R., Chen, X. R., Wang, Y., & Liu, H. (2025). A review of the mechanism, diagnosis, and treatment of *Naegleria fowleri* infection. *Frontiers in Microbiology*, *16*, Article 1686695. https://doi.org/10.3389/fmicb.2025.1686695

[43] Butt, C. G. (1966). Primary amebic meningoencephalitis. *New England Journal of Medicine*, *274*(26), 1473–1476. https://doi.org/10.1056/NEJM196606302742605

[44] Carter, R. F. (1970). Description of *Naegleria* sp. isolated from two cases of primary amoebic meningoencephalitis. *The Journal of Pathology*, *100*(4), 217–244. https://doi.org/10.1002/path.1711000403

[45] World Health Organization. (2003). *Guidelines for safe recreational water environments: Vol. 1. Coastal and fresh waters*.

[46] Pond, K. (2005). *Water recreation and disease: Plausibility of associated infections*. IWA Publishing.

[47] Martinez, A. J., & Visvesvara, G. S. (1997). Free-living, amphizoic and opportunistic amebas. *Brain Pathology*, *7*(1), 583–598. https://doi.org/10.1111/j.1750-3639.1997.tb01082.x

[48] Kim, J. H., Jung, S. Y., Lee, Y. J., & Park, S. J. (2015). Effect of therapeutic hypothermia on the course of primary amebic meningoencephalitis. *Neurology*, *84*(2), 210–211. https://doi.org/10.1212/WNL.0000000000001125

[49] Vargas-Zepeda, J., Gomez-Alcala, A. V., Vasquez-Morales, J. A., Licea-Amaya, L., De Jonckheere, J. F., & Lares-Villa, F. (2005). Successful treatment of *Naegleria fowleri* meningoencephalitis using intravenous amphotericin B, fluconazole and rifampicin. *Archives of Medical Research*, *36*(1), 83–86. https://doi.org/10.1016/j.arcmed.2004.11.003

[50] Centers for Disease Control and Prevention. (2024). *Naegleria fowleri: Resources for health professionals*. https://www.cdc.gov/parasites/naegleria/health-professionals.html